药物联合新辅助化疗(ET)对三阴乳腺癌患者生存状态的改善及其疗效评价

目的:观察表柔比星和多西紫杉醇联合新辅助化疗(ET)对三阴乳腺癌患者生存状态的改善及其疗效,评价该化疗方案在三阴乳腺癌的化疗中加入紫杉类化疗药物的可行性。方法:收集我院2011年1月至2011年12月收治的300例乳腺癌患者,将患者随机分为两组,研究组及对照组,每组各150例。对照组采用单纯表柔比星,研究组采用新辅助化疗的方案(ET方案),随访12个月,统计两组临床疗效并进行评价。结果:研究组完全缓解率(92.00%)明显高于对照组的78.00%,疾病无缓解率(1.33%)及疾病恶化率(0%)明显低于对照组的14.00%及1.33%,差异具有统计学意义(P0.01)。随访期间,对照组患者68例(45.3%)复发或转移,而研究组患者35例(23.3%)出现复发或远处转移,两者比较,差异显著(P0.001)。结论:在三阴乳腺癌的化疗中加入紫杉类化疗药物是可行的,效果显著。

The Improvement of Survival State and Its Curative Effect Evaluation ofDrug Combined with New Adjuvant Chemotherapy (ET)for the Triple Negative Breast Cancer

Objective： To observe the docetaxel and epirubicin combined with new adjuvant chemotherapy （ET） the improvement of survival state and its curative effect evaluation, to evaluate the feasible of triple negative breast cancer chemotherapy to join yew chemotherapeutic drugs. Methods： 300 patients with breast cancer admitted in our hospital between January 2011 and December 2011 were collected,and randomly divided into two groups, the trealanent group and control group, with 150 cases in each group. Control group was adopted Epirubicin, the treatment group was used the new adjuvant chemotherapy scheme （ET）, the followed up time were 12 months, the clinical curative effect and evaluation in two groups were counted. Results： The complete remission rate in the treatment group （92.00%）was obviously higher than that in the control group of 78.00%, disease remission rate （1.33%） and disease progression ra- te （0%） were significantly lower than the control group of 14.00% and 1.33%, the difference was highly significant （P 〈 0.01）. Follow-up period, the control group of 68 cases （45.3%） patients were recurrence or metastasis, and the treatment group of 35 patients with recurrence or distant metastasis （23.3%） appeared, the comparison had significant difference （P 〈 0.001）. Conclusion： Adding Docetaxel in triple negative breast cancer chemotherapy chemotherapeutic drugs is feasible and effective.